• About
• Links
• Contact
• Sitemap
• 

Monoclonal Antibodies in Cancer Therapy 2009-2024

Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains. The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies. The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both developed and emerging geographical markets. Currently, new technologies are removing some of the drawbacks that monoclonal antibody therapies have experienced. Leading pharma companies are already investing heavily in monoclonal antibody technologies. Monoclonal antibodies with great commercial potential are in the oncology pipeline, as  Monoclonal Antibodies in Cancer Therapy 2009-2024  explains.

The period 2009 to 2019 will reveal volatility in the monoclonal antibody therapies market as current-leading products reach peak sales and new-generation drugs emerge. Will technological advances further benefit monoclonal antibody-based therapies and their overall sales? Will better immunotoxicity profiles lead to higher revenues for products? What types of monoclonal antibody therapies will enter the market from 2009 onwards, and can they dominate this market? Where will the opportunities lie, and what are the market drivers and restraints? This report will provide you with the information that you need to understand current trends and future possibilities. In particular, we discuss prospects for the following products:

• Rituxan
• Avastin
• Herceptin
• Erbitux
• Vectibix
• Campath.

Comprehensive analysis of this important market area

Monoclonal Antibodies in Cancer Therapy 2009-2024 examines that market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures included. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion.

Why you should buy this report

Benefits that you will gain from Monoclonal Antibodies in Cancer Therapy 2009-2024 include:

• Appraisal of the existing market for monoclonal antibody cancer therapies
• Forecasting and discussion of market values for monoclonal antibody cancer therapies, including detailed sales forecasts for 2009 to 2024
• Discussion of leading products, including sales forecasts, growth and market share analyses
• Analyses of 10 leading national markets for monoclonal antibody cancer therapies, including China and India, with forecasted sales and market shares
• Coverage of R&D pipeline developments, with trends to watch out for
• Exclusive interviews with a leading academic and mAbs journal chief editor and with a chief scientist in oncology within a leading pharma company
• Informed analyses of strengths and weaknesses of the technologies from 2009 onwards
• Balanced assessments of commercial drivers and restraints that the market area faces from 2009 to 2024.

Table of Contents

1 Executive Summary

• 1.1 Aims of this Report
• 1.2 Brief Overview of the Chapters in this Report

2 Monoclonal Antibodies for Cancer Therapy

• 2.1 Oncology is the Fifth-Largest Therapeutic Class Worldwide by Total Sales
• 2.2 The Oncology Market is Expanding
• 2.3 Monoclonal Antibodies
  • 2.3.1 What are Monoclonal Antibodies?
  • 2.3.2 How do Monoclonal Antibody Therapies Work?
• 2.4 Categories of Monoclonal Antibodies for Therapeutic Use
  • 2.4.1 Murine Antibodies
  • 2.4.2 Chimeric and Humanised Antibodies
  • 2.4.3 Human Antibodies
  • 2.4.4 Immunogenicity
• 2.5 Current Monoclonal Antibody Cancer Therapies
  • 2.5.1 Rituxan/MabThera
  • 2.5.2 Avastin
  • 2.5.3 Herceptin
  • 2.5.4 Erbitux
  • 2.5.5 Vectibix
  • 2.5.6 Campath
  • 2.5.7 Mylotarg
  • 2.5.8 Zevalin and Bexxar
  • 2.5.9 The Market Shares of Naked vs. Conjugated Monoclonal Antibodies
  • 2.5.10 The Market for Monoclonal Antibody Therapies is Growing.

3 Total World Market 2009-2024

• 3.1 Summary of Key Findings
• 3.2 Biotech is a Rapidly-Expanding Market
• 3.3 Monoclonal Antibodies are a Central Part of the Biotech Market
• 3.4 Oncology - A Major Sales Driver in the Mab Sector
• 3.5 Total World Market in 2008
• 3.6 Predicted Sales from 2009-2024
• 3.7 The Big Three
• 3.8 Generic Competition
• 3.9 Chimeric Antibodies in Decline
• 3.10 The Shift Towards Human Antibodies

4 Key Products Analysis

• 4.1 Overview: Strong Pipeline Means Competition Will Increase
• 4.2 Roche/Genentech Dominated the Market in 2008
• 4.3 Rituxan/MabThera (Roche/Genentech)
  • 4.3.1 Will Rituxan Continue Steady Growth over the Next Five Years?
• 4.4 Avastin (Roche/Genentech)
  • 4.4.1 Broadened Profile and Patient Base
  • 4.4.2 Continued Growth Despite Competition
• 4.5 Herceptin (Roche/Genentech)
  • 4.5.1 Strong Competition in the R&D Pipeline
• 4.6 Erbitux (Merck/Imclone)
  • 4.6.1 Aiming for the Top Three
• 4.7 Vectibix (Amgen)
  • 4.7.1 The K-RAS Issue
• 4.8 Campath (Bayer Schering AG)
  • 4.8.1 Future Increase in Revenue?

5 SWOT Analysis for the Monoclonal Antibody Oncology Therapies Market

• 5.1 Principal Drivers
  • 5.1.1 Increasing Prevalence and High Economic Costs of Cancer
  • 5.1.2 MAb Therapy Presents Lower Risk of Adverse Effects
  • 5.1.3 Combining Existing Products
  • 5.1.4 Biologicals vs. Chemically-Derived Pharmaceutical Products
  • 5.1.5 Promising Pipelines
  • 5.1.6 Improvements in Accessibility
  • 5.1.7 New Production Methods will Reduce Costs
• 5.2 Principal Restraints
  • 5.2.1 Development Costs - a High Barrier of Entry
  • 5.2.2 Mode of Administration is a Limiting Factor
  • 5.2.3 Insufficient Efficacy as a Single Agent
  • 5.2.4 Immunogenicity - the Rise of Humanised and Human Monoclonal Antibodies
  • 5.2.5 Financial Limitations in Research and Development
  • 5.2.6 Adverse Events - Safety Concerns
  • 5.2.7 Competition for Prime Drug Targets

6 MAbs in the Leading Pharmaceutical Markets

• 6.1 USA
• 6.2 Europe
• 6.3 Other Countries
• 6.3.1 India and China

7 The Monoclonal Antibody Cancer Therapies Pipeline

• 7.1 New Technology - Monoclonal Antibody Fragments
  • 7.1.1 Bispecific T-Cell Engagers
  • 7.1.2 Tandabs
• 7.2 Conjugated vs. Naked Antibodies
• 7.3 The Future of Human MAbs
• 7.4 Competition for Prime Drug Targets
  • 7.4.1 Tailored Medicine
• 7.5 Solid Pipeline
• 7.6 Products to Watch
  • 7.6.1 Roche's Winning Pipeline
  • 7.6.2 Genmab and GlaxoSmithKline's Arzerra/HuMax-CD20
  • 7.6.3 Amgen's AMG 162

8 Interviews with Relevant Experts

• 8.1 Dr Janice M. Reichert, Tufts University and Editor-in-Chief of the Journal mAbs
  • 8.1.1 Major Challenges and Opportunities for Monoclonal Antibody Cancer Therapies
  • 8.1.2 Future Developments and Pipelines
  • 8.1.3 The Effect of Biosimilars
• 8.2 Dr David Blakey, AstraZeneca
  • 8.2.1 The Future of Humanised and Fully-Human Antibodies
  • 8.2.2 Therapeutic Antibody Fragments vs. Full-Length IgGs
  • 8.2.3 Major Opportunities in Monoclonal Antibody Cancer Therapies

9 Conclusions

• 9.1 The MAb Market is Strong and Expected to Grow Stronger
• 9.2 Expansion into New Markets
• 9.3 Personalised Treatments Emerging
• 9.4 Growth Will Eventually Slow as Expansion of the Market Drives Prices Down
• 9.5 Outlook for the Future

List of Tables

• Table 2.1 Summary of Types of Monoclonal Antibodies for Cancer Therapy
• Table 2.2 Targets and Indications for Selected FDA-Approved Antibodies
• Table 3.1 Top Selling FDA Approved Antibodies, 2008
• Table 3.2 Leading Monoclonal Antibodies for Oncology Therapies, Sales ($bn) and Market Shares (%), 2008
• Table 3.3 Predicted Sales ($bn) for the World Market, 2009-2024
• Table 3.4 Predicted Growth Rate (%) for the World Market, 2009-2024
• Table 3.5 World Sales ($bn) and Market Shares (%) for the Different Types of Oncology Monoclonal Antibodies, 2008
• Table 3.6 Market Shares (%) for Chimeric, Humanised and Human Monoclonal Antibodies, 2014-2024
• Table 4.1 Predicted Sales ($bn) for the World Market, 2009-2016
• Table 4.2 Predicted Sales ($bn) for the World Market, 2017-2024
• Table 4.3 Market Shares (%) and CAGR (%) for Selected Products, 2008 and 2014
• Table 5.1 SWOT Analysis, 2009-2024
• Table 5.2 Side Effects of Monoclonal Antibody Therapy
• Table 6.1 Leading Regions of the Monoclonal Antibody Anticancer Therapies Market, Sales ($bn) and Market Shares (%), 2008 and 2014
• Table 7.1 Selected Phase III and Pre-Registration Anticancer Monoclonal Antibodies, 2008
• Table 9.1 Global Monoclonal Antibody Anticancer Therapies, Sales ($bn) and Growth (%), 2008-2014

List of Figures

• Figure 2.1 Sales ($bn) of Naked vs. Conjugated Monoclonal Antibodies, 2008
• Figure 3.1 Market Shares (%) for the Main Categories of the Monoclonal Antibody Market for 12 Months up to Q3 2008
• Figure 3.2 Sales ($bn) for the Top Three Monoclonal Antibody Oncology Therapies, 2005-2008
• Figure 3.3 Sales ($bn) for Monoclonal Antibody Oncology Therapies for 12 Months up to Q3 2008
• Figure 3.4 Market Shares (%) for Monoclonal Antibody Oncology Therapies for 12 Months up to Q3 2008
• Figure 3.5 Predicted Sales ($bn) for the World Market, 2009-2024
• Figure 3.6 Predicted Growth (%) of the World Market, 2009-2014
• Figure 3.7 Predicted Sales ($bn) for the Big Three: Rituxan, Avastin and Herceptin, 2009-2014
• Figure 3.8 Sales ($bn) for Different Types of Monoclonal Antibodies for Oncology, 2008
• Figure 3.9 Market Shares (%) for Different Types of Monoclonal Antibodies for Oncology, 2008
• Figure 3.10 Pipeline Drugs (Phase II and III) by Antibody Type, 2008
• Figure 3.11 Predicted Market Shares (%) for Chimeric, Humanised and Human Monoclonal Antibodies, 2014-2024
• Figure 4.1 Market Shares (%) for Companies in the Monoclonal Antibody Oncology Therapies Area, 2008
• Figure 4.2 Sales ($bn) for Rituxan, 2005-2008
• Figure 4.3 Sales ($bn) for Rituxan, 2009-2014
• Figure 4.4 Market Share (%) for Rituxan, 2009-2014
• Figure 4.5 Sales ($bn) for Rituxan/MabThera, 2009-2024
• Figure 4.6 Sales ($bn) for Avastin and Rituxan, 2009-2024
• Figure 4.7 Sales ($bn) for Avastin, 2005-2008
• Figure 4.8 Market Share (%) for Avastin, 2009-2014
• Figure 4.9 Sales ($bn) for Avastin, 2009-2024
• Figure 4.10 Sales ($bn) for Herceptin, 2005-2008
• Figure 4.11 Sales ($bn) for Herceptin, 2009-2024
• Figure 4.12 Market Share (%) for Herceptin, 2008-2014
• Figure 4.13 Sales ($bn) for Erbitux, 2005-2008
• Figure 4.14 Sales ($bn) for Erbitux, Herceptin and Rituxan, 2009-2024
• Figure 4.15 Sales ($bn) for Erbitux, 2009-2024
• Figure 4.16 Market Share (%) for Erbitux, 2009-2014
• Figure 4.17 Sales ($bn) for Vectibix, 2009-2014
• Figure 4.18 Market Share (%) for Vectibix, 2009-2014
• Figure 4.19 Sales ($bn) for Vectibix, 2009-2024
• Figure 4.20 Sales ($bn) for Campath, 2005-2008
• Figure 4.21 Sales ($bn) for Campath, 2009-2024
• Figure 4.22 Market Share (%) for Campath, 2009-2014
• Figure 6.1 Leading Pharmaceutical Markets, Sales ($bn), 2008, 2014, 2019 and 2024
• Figure 6.2 Leading Pharmaceutical Markets, Market Shares (%), 2008, 2014, 2019 and 2024
• Figure 6.3 Leading Pharmaceutical Markets, CAGR (%), 2008-2014
• Figure 6.4 Comparisons of the US, European, Chinese and Indian Markets, Market Shares (%), 2008-2024
• Figure 7.1 Pipeline Drugs (Phase II) by Indication, 2008
• Figure 7.2 Pipeline Drugs (Phase III) by Indication, 2008

Other users found this report page using the following search terms: Rituxan Avastin Herceptin Erbitux Vectibix Campath monoclonal 2009 antibody antibodies therapy cancer sales market herceptin campath

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.